Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Estimates By $0.01 EPS

Spero Therapeutics (NASDAQ:SPRO) released its earnings results on Wednesday. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01, FiscalAI reports. Spero Therapeutics had a net margin of 24.90% and a return on equity of 35.58%.

Spero Therapeutics Trading Down 3.3%

Shares of NASDAQ SPRO traded down $0.04 during mid-day trading on Wednesday, reaching $1.19. The company had a trading volume of 764,878 shares, compared to its average volume of 874,169. The firm has a 50 day simple moving average of $1.93 and a two-hundred day simple moving average of $2.30. Spero Therapeutics has a 52-week low of $1.08 and a 52-week high of $3.08. The stock has a market cap of $68.90 million, a P/E ratio of 4.96 and a beta of 1.55.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Wall Street Zen cut shares of Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a report on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

Institutional Trading of Spero Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. GSK plc acquired a new stake in shares of Spero Therapeutics in the 4th quarter valued at about $21,414,000. Vanguard Group Inc. increased its position in Spero Therapeutics by 2.0% during the third quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company’s stock worth $3,741,000 after buying an additional 39,474 shares during the period. State Street Corp lifted its stake in Spero Therapeutics by 10.1% in the fourth quarter. State Street Corp now owns 210,151 shares of the company’s stock valued at $490,000 after buying an additional 19,200 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Spero Therapeutics in the third quarter valued at approximately $283,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Spero Therapeutics in the fourth quarter valued at approximately $306,000. Institutional investors and hedge funds own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug?resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram?negative pathogens.